BlackRock, Inc. Amends Schedule 13G/A for Jade Biosciences Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Jade Biosciences Inc., reporting a decrease in its ownership stake. As of September 30, 2025, BlackRock owns 2,150,203 shares, representing 6.6% of the outstanding common stock. This marks a significant decrease from its previous holdings, with a reduction of 8,271,612 shares and a 79.37% drop in value. The filing indicates that BlackRock acquired and holds these securities in the ordinary course of business, without the intent to influence control of the issuer. The amendment includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.